% of Cases treated with Radiotherapy
UKIACR average (population) | UKIACR average (country) | England | Scotland | Wales1 | Northern Ireland | Republic of Ireland | |
---|---|---|---|---|---|---|---|
All invasive xnmsc | 20.9% | 20.3% | 21.0% | 19.5% | 20.5% | 20.3% | |
All xnmsc 0-24 | 15.5% | 15.2% | 15.5% | 16.6% | 13.1% | 15.5% | |
All xnmsc 25-59 | 24.5% | 24.9% | 24.4% | 24.2% | 26.3% | 24.5% | |
All xnmsc 60-79 | 23.0% | 22.0% | 23.3% | 21.2% | 22.0% | 21.4% | |
All xnmsc 80+ | 12.0% | 11.3% | 12.2% | 10.0% | 11.4% | 11.6% | |
Haematology | 9.2% | 9.0% | 9.3% | 7.8% | 7.5% | 11.6% | |
Head and Neck | 59.3% | 57.1% | 60.7% | 47.5% | 60.5% | 59.6% | |
Lower GI | 13.3% | 13.5% | 13.2% | 14.3% | 12.2% | 14.4% | |
Upper GI | 18.5% | 16.2% | 19.0% | 16.1% | 21.4% | 8.2% | |
HPB | 2.4% | 2.9% | 2.4% | 1.7% | 2.9% | 4.7% | |
Trachea, Bronchus & Lung | 26.8% | 26.6% | 26.7% | 26.9% | 28.4% | 24.6% | |
Melanoma of skin | 0.7% | 0.6% | 0.8% | 0.3% | 0.6% | 0.9% | |
Breast | 38.0% | 37.7% | 37.9% | 39.5% | 38.7% | 34.8% | |
Cervix | 42.1% | 47.8% | 41.1% | 45.7% | 45.3% | 59.1% | |
Other Female Genitals | 16.1% | 17.2% | 15.8% | 15.8% | 20.5% | 16.9% | |
Prostate | 19.3% | 14.8% | 20.8% | 7.0% | 12.3% | 19.2% | |
Kidney | 5.4% | 6.5% | 5.3% | 4.8% | 7.1% | 9.0% | |
Bladder | 17.7% | 16.9% | 17.9% | 16.5% | 17.3% | 16.0% | |
Brain and CNS | 48.2% | 45.2% | 49.0% | 45.5% | 43.5% | 43.0% | |
Thyroid & other endocrine glands | 32.3% | 28.9% | 33.4% | 22.1% | 39.7% | 20.4% | |
CUP | 11.5% | 10.1% | 11.8% | 9.7% | 11.8% | 7.1% | |
Other invasive cancer | 15.2% | 14.4% | 15.3% | 14.5% | 16.3% | 11.5% | |
Breast in situ | 32.7% | 35.8% | 32.1% | 39.7% | 30.3% | 41.1% | |
Cervix in situ | 0.0% | 0.1% | 0.0% | 0.0% | 0.2% | 0.0% | |
Other tumours | 1.1% | 1.3% | 1.2% | 0.3% | 1.4% | 2.4% | |
Non-Melanoma Skin Cancer | 1.8% | 1.1% | 2.0% | 0.4% | 1.1% | 0.8% |